Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2000-08-31
2009-12-08
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S179000, C552S523000, C552S553000, C552S610000
Reexamination Certificate
active
07629334
ABSTRACT:
The use of mesoprogestins as pharmaceutical components for the manufacture of a medicament for hormone replacement therapy (HRT) and as components for the combined use together with an estrogen for the manufacture of a medicament for HRT as well as in respective HRT-methods and methods of treating hormone deficiency and hormone irregularity symptoms. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. J867, J912, J956 and J1042 are the mesoprogestins preferred herein.
REFERENCES:
patent: 4670426 (1987-06-01), Zor et al.
patent: 5468736 (1995-11-01), Hodgen
patent: 5469836 (1995-11-01), Greenall
patent: 5693628 (1997-12-01), Schubert et al.
patent: 6040340 (2000-03-01), Chwalisz et al.
patent: 4332284 (1995-03-01), None
patent: 4332283 (1995-04-01), None
patent: 19610635 (1997-09-01), None
patent: 19809845 (1998-03-01), None
patent: 0648779 (1995-04-01), None
patent: WO 93/21926 (1993-11-01), None
patent: WO 9612494 (1996-05-01), None
patent: WO 9749407 (1997-12-01), None
patent: WO 9945023 (1999-09-01), None
Jewgenow et al., Comparitive Binding Affinity Study of Progestins to the Cytosol Progestin Receptor of Endometrium in Different Mammals, General and Comparitive Endocrinology 110, 118-124, (1998).
Fertility and Sterility, 1999 vol. 71(4) Supp 1 Page 95.
Abstract—Schneider B., Exp.Clin. Endocrinol.Diabetes (106, Suppl. 1, S52, 1998).
Bruce A. Lessey, M.D., PhD., Medical management of endometriosis and infertility, Fertility and Sterility, Jun. 2003, vol. 73(6) pp. 1089-1096.
Chwalisz Kristof
Elger Walter
Schubert Gerd
Bayer Schering Pharma Aktiengesellschaft
Millen White Zelano & Branigan P.C.
Padmanabhan Sreeni
Ramachandran Umamaheswari
LandOfFree
Mesoprogrestins (progesterone receptor modulations) as a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mesoprogrestins (progesterone receptor modulations) as a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mesoprogrestins (progesterone receptor modulations) as a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4149157